Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 Short Communication

Recurrence of COVID-19 after recovery? A case series in health care workers, France

Souheil Zayet*, Pierre-Yves Royer, Lynda Toko, Alix Pierron, Vincent Gendrin, Timothée Klopfenstein**

Infectious Disease Department, Nord Franche-Comté Hospital, France

ARTICLE INFO

Article history:
Received 18 January 2021
Accepted 18 February 2021
Available online 2 March 2021

Keywords:
COVID-19
SARS-CoV-2
Health care worker
Recurrence
Recovery

Abstract

We describe 3 cases of coronavirus disease 2019 in health care workers in France involving presumed clinical and microbiological recurrence after recovery. All patients were immunocompetent with clinical mild form. These cases highlight the possibility of coronavirus disease—recurrence.

© 2021 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In hospitals, there is a considerable risk of contracting COVID-19 infection among health care workers (HCWs) [1] with a high incidence of mild to moderate forms in this population [2]. The possibility of a reactivation of COVID-19 raises a major public health concern since it could contribute to the spread of the virus in the population, especially in hospitals. In this rapidly emerging epidemic, several case reports describe clinical and/or microbiological recurrences in SARS-CoV-2-infected patients [3–8]. We report a case series of presumed clinical and microbiological recurrence after recovery in 3 HCWs with mild forms of COVID-19.

1. Materials and methods

In our facility, 312 HCWs were infected during the first wave [9] between March 1st and May, 30th, 2020. During the second wave [10] (from October 1st, to December 7th, 2020), 219 of our HCWs have tested positive with SARS-CoV-2 until December, 03rd. Among these 219 HCWs, 3 had already been infected with SARS-CoV-2 during the first wave.

2. Results

These 3 patients were females working in different departments with a median age of 43 [32–57] years. They had no comorbidities, except one patient with asthma. During the first episode, the median duration of symptoms was 10 [7–14] days with a complete recovery. All had a negative RT-PCR between the two episodes. All patients returned to work in COVID units and had possible COVID-19 re-exposure. The median interval between the two episodes was 213 [155–236] days. Clinical and microbiological data were summarized in the Fig. 1 and Table 1. All RT-PCR testing were administered in our laboratory and all of the samples were subjected to the same assays.

On March 25th, 2020, a 57-year-old female with a past history of well-controlled asthma (treated with salbutamol) sought care for influenza-like illness (ILI) including myalgia, fatigue and sore throat associated to a productive cough with anosmia, dysgeusia and diarrhea. Real-time reverse transcription PCR (RT-PCR) on a nasopharyngeal swab specimen confirmed COVID-19. Fever and other symptoms disappeared after 2 weeks. On June 23rd, her SARS-CoV-2 serology (obtained upon patient's request) was positive for IgG and IgM. SARS-CoV-2 RT-PCR follow-up test (carried out on November 20th) was negative. On November 26th, the patient was...
presented for myalgia and fatigue. She also complained of dyspnea. On November 27th, RT-PCR was positive; RNA nucleocapsid gene (N) of SARS-CoV-2 was detected with a cycle threshold (Ct) value of 40. On December 3rd, a follow up RT-PCR was negative.

On April 14th, 2020, a 40-year-old female with no past history sought care for fever at 38.5°C, chills, myalgia and fatigue. All symptoms regressed after 8 days. COVID-19 was diagnosed from clinical presentation and serology testing (performed on June 18th, which was positive for IgG). SARS-CoV-2 RT-PCR testing was not performed initially. She only performed a follow-up nasopharyngeal swab, which proved to be negative. On November 26th, the patient was represented with ILI, retro-orbital headache, anosmia and dysgeusia associated to respiratory symptoms such as non-productive cough, chest pain and dyspnea with a normal pulmonary auscultation. She

Table 1
Demographic, clinical characteristics and laboratory findings of COVID-19 first and 2nd episodes, from onset of first episode (D1) to last follow-up, Nord Franche-Comte Hospital, France, 2020.

| Patient 1 | Patient 2 | Patient 3 |
|-----------|-----------|-----------|
| **Age, y** | 57        | 40        | 32        |
| **Sex**   | F         | F         | F         |
| **Comorbidities** | Asthma (HCW) | None (HCW) | None (HCW) |
| **Clinical presentation** | ILI without fever-AO-DG-cough-sputum production-diarrhea | ILI, chills | ILI |
| **RT-PCR® SARS-CoV-2** | Days from onset | Days from 1st onset | Days from 1st onset |
| | CT if available | Results | Results |
| | D6 | POSITIVE (E 27.66 – N NA RdRP 25.62) | 59 | POSITIVE IgG IgM | 61 | POSITIVE IgG |
| **Serology** | | | | | 236 | NEGATIVE |
| **RT-PCR® SARS-CoV-2 (follow-up)** | Days from onset | Days from 1st onset | Days from 1st onset |
| | Results | Results | Results |
| | None | NEGATIVE | None |
| **Treatment** | Duration of symptoms | Administration | Duration of symptoms |
| | | Myalgia-fatigue-dyspnea | ILI-chills-headache-tearing-AO-DG-cough-chest pain-dyspnea- |
| | Days from 1st onset (clinical recurrence) | Days from 2nd onset | Days from 2nd onset |
| | CT if available | CT if available | CT if available |
| | 243 | 8 | POSITIVE (E NA – N 40 RdRP NA) |
| **RT-PCR SARS-CoV-2** | Days from 1st onset | Days from 1st onset | Days from 1st onset |
| | | | |
| | None | None | None |
| **Treatment** | Administration | Administration | Administration |
| | None | None | None |

Abbreviations: AO: anosmia; COVID-19: coronavirus disease 2019; D: day; DG: dysgeusia; ILI: influenza-like illness (fever + myalgia/arthralgia + fatigue + sore throat + nasal congestion); HCW: Health care worker; NA: not available; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

* RT-PCR: real-time reverse transcription Polymerase Chain Reaction: cycle threshold (CT), envelope gene (E), nucleocapsid gene (N), ARN polymerase gene (RdRP), specific Open Reading Frame (ORF)1.
specified that she had recently been in contact with a known case of SARS-CoV-2. On December 03\textsuperscript{rd}, SARS-CoV-2 RT-PCR was positive with detection of RNA envelope gene (E) and specific Open Reading Frame (ORF)1 at Ct values of 36.4 and 36.93, respectively.

On June 1st, a 32-year-old female with no past medical history sought care for IIL related to COVID-19. On September 9th, her serology (obtained upon patient’s request) was compatible with a previous SARS-CoV-2 infection (IgG 20.2 U/mL). On November 11th, she was tested during a collective screening in her hospital department after an outbreak with several cases among the HCWs. SARS-CoV-2 RT-PCR was negative. On November 27th, the patient developed similar clinical presentation to the first episode associated to anosmia, dysgeusia and gastro-intestinal symptoms such as vomiting and diarrhea. On December 04th, SARS-CoV-2 RT-PCR was positive with detection of RNA gene and (N) at Ct values of 38.

3. Discussion

In our case series, all patients presented two episodes of SARS-CoV-2 infection separated by a symptom-free interval with a median duration between the two episodes of about 8 months. During this interval, RT-PCR follow-up was negative in all cases. All of our patients have strong clinical and microbiological evidence that it is indeed a COVID-19 recurrence, more than the hypothesis of prolonged nucleic acid conversion in COVID-19 or traces of viral RNA. To explain this, several hypothesis were put forward such as viral relapse or inflammatory rebound [3,11]. Immunity protective role from re-infection along with definitive viral clearance is uncertain [12,13]. One hypothesis would be that these episodes are linked to the persistence of the virus in a reservoir (sanctuary site) with viral rebound, as previously suggested for other viral infections [14]. However, our cases are less likely to reflect persistent viral RNA shedding, including shedding related to non-virulent virus. Recent studies reported that the median duration of prolonged SARS-CoV-2 RNA shedding in COVID-19 patients was about 30 days [15], unlike our HCWs’ presentation with a long median interval between the two episodes (more than 7 months) and a confirmed clinical and microbiological recovery. In addition to that, risk factors of reactivation would probably include immunosuppression [3,5,6]. In a French cohort including 11 COVID-19 patients with clinical recurrences, 3 of them had received recent chemotherapy and/or rituximab and didn’t develop SARS-CoV-2 antibodies more than 3 weeks after severe symptoms [3]. This probably contributes to impair viral clearance and favors reactivation. In contrast to these cases, our patients were immunocompetent and developed SARS-CoV-2 antibodies, after the first episode. Several authors have described recurrence of COVID-19 in HCWs [3,7], Fernandes et al. have described six cases of healthcare professionals in Brazil who recovered but again presented symptoms of COVID-19 with mild-to-moderate forms, with new RT-PCR positive results [7]. Gousseff et al. have reported 4 cases of HCWs with separate mild COVID-19 forms. They suggested that ‘re-infection’ is due to the prolonged exposure given the fact that the immune response may faint [3]. Finally, some authors have suggested that recurrence may be explained by inflammatory rebound [3,11]. By using mathematical models to study the pathogenic features of SARS-CoV-2 infection, cells and immune responses, Wang et al. have demonstrated that when the initiation of seroconversion is late or slow, the model predicts viral rebound and prolonged viral persistence [11].

Finally, we thought that these data are fairly strong with clinical confirmation and serological evidence of prior infection of all three cases. However, the laboratory confirmation of that re-infection is a bit weak (Ct’s very high); although the Ct values may be expected to be high on reinfection with a potentially waning antigen response. Another possible limitation is that without genomic analyses of the isolates from the initial and putative reinfection episodes, it cannot be determined with certainty that SARS-CoV-2 reinfection occurred in these patients [16,17]. Unfortunately, the different strains responsible for the first and second episodes in our patients were not available for sequencing. The occurrence of these cases one month before first description of the New UK (20I/S01Y.V1) and South African (20H/501Y.V2) SARS-CoV-2 variants in France [18] rules out the hypothesis of a reinfection with a new SARS-CoV-2 variant.

To conclude, the recurrence of the SARS-CoV-2 in patients who have recovered from COVID-19 is possible, but the mechanism leading to these re-positive cases is still unclear. These cases emphasize the importance of active surveillance of SARS-CoV-2 RNA for infection assessment, particularly in HCWs to reduce in-hospital transmissions.

Contributors

SZ and PYR collected the epidemiological and clinical data. SZ drafted the figure. SZ and TK drafted the manuscript. TK, AP, LT and VG revised the final manuscript.

We thank all patients involved in the study and especially Dr Quentin Lepillier for his support and valuable feedback.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

All authors declare no competing interests.

References

[1] Sahu AK, Amrithanand VT, Mathew R, Aggarwal P, Nayer J, Bhoi S. COVID-19 in health care workers - a systematic review and meta-analysis. Am J Emerg Med 2020;38(9):1727–31.
[2] Kadiane-Oussou NJ, Klopfenstein T, Royer P-Y, Toko L, Gendrin V, Zayet S. COVID-19: comparative clinical features and outcome in 114 patients with or without pneumonia (Nord Franche-Comte Hospital, France). Microb Infect 2020 Oct 10;22(10):662–5.
[3] Gousseff M, Penot P, Gallay L, Batishe D, Benech N, Bouiller K, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? J Infect 2020 Nov;81(5):816–46.
[4] Dao TL, Hoang VT, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 2020 Oct 28;40(1):13–25.
[5] He F, Luo Q, Lei M, Fan L, Shao X, Hu K, et al. Successful recovery of recurrence of SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. Clin Rheumatol 2020 Sep;39(9):2803–10.
[6] Luciana M, Bentivegna E, Spontarelle V, Lamberti G, Del Porto F, et al. Recurrent Covid-19 Pneumonia in the course of chemotherapy: consequence of a weakened immune system? J Med Virol 2020 Nov 28;93(4):1882–4.
[7] Fernandes Valente Takeda C, Moura de Almeida M, Conçalves de Aguia Gomes R, Cine Souza T, Alves de Lima Mota M, Pamplona de Goes Cavalcanti L, et al. Case report: recurrent clinical symptoms of COVID-19 in healthcare professionals: a series of cases from Brazil. Am J Trop Med Hyg 2020;103(5):1993–6.
[8] Kim AY, Gandhi RT. Re-infection with SARS-CoV-2: what goes around may come back around. Clin Infect Dis Off Publ Infect Dis Soc Am 2020 Oct 9: ciaa1541. https://doi.org/10.1093/cid/ciaa1541. Online ahead of print.
[9] Fouillet A, Pontais I, Caserio Schönemann C. Excess all-cause mortality during the first wave of the COVID-19 epidemic in France, March to May 2020 [Internet] Eurosurveillance 2020 Aug 27;25(34):2001485.
[10] Nergaard SK, Vestergaard LS, Nielsen J, Richter L, Schmid D, Bastos N, et al. Real-time monitoring shows substantial excess all-cause mortality during second wave of COVID-19 in Europe, October to December 2020 [Internet] Eurosurveillance 2021 Jan 14;26(2):2002023.
[11] Wang S, Pan Y, Wang Q, Mao H, Brown AN, Rong L. Modeling the viral dynamics of SARS-CoV-2 infection. Math Biosci 2020 Oct;328:108438.
[12] Casanova J-L, Su HC. COVID human genetic effort. A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. 11 Cell 2020;181(6):1194–9.
[13] Grifoni A, Weiskopf D, Ramirez SL, Mateus J, Dan JM, Modderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. 25 Cell 2020;181(7):489–501 e15.
[14] Mahy D, McElroy AK, de Clerck H, Günther S, van Griensven J. Ebola virus disease. 02 Lancet Lond Engl 2019;393(10174):936–48.
[15] Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon. J Med Virol 2020 Nov;92(11):2286–7.
[16] Gupta V, Bhoyar RC, Jain A, Srivastava S, Upadhyay R, Imran M, et al. Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. Clin Infect Dis Off Publ Infect Dis Soc Am 2020 Sep 23:ciaa1451. https://doi.org/10.1093/cid/ciaa1451. Online ahead of print.
[17] Shastri J, Parikh S, Agarwal S. Whole genome sequencing confirmed SARS-CoV-2 reinfections among healthcare workers in India with increased severity in the second episode. 2020 Sep 21 [cited 2021 Feb 17]; Available from: https://europepmc.org/article/ppr/ppr244433.
[18] Eurosurveillance editorial team. Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2021 Jan;26(3).